Q&A with Anna Baecklund, CTO & Founder at Oppioo

Anna Baecklund,
Anna Baecklund, CTO & Founder at Oppioo, is a Data Scientist Leader, A skilled communicator capable of explaining complex issues with clarity to diverse audiences. With MSc in engineering physics, Anna is responsible for leading innovation using data science including the development of new insights, advanced modelling techniques, and AI capabilities. With Oppio, An AI companion app, she aims to motivate cancer patients who want to speed up and improve their rehab.

AI-enabled precision health tools can identify potential risks and suggest preventative interventions.

MEDIA7: You have a long career experience in diverse fields ranging from teaching physics and mathematics to being a Data Scientist Leader. How has all this experience helped you play your current role at Oppioo?
ANNA BAECKLUND:
My diverse set of experiences has helped a lot working with Oppioo; all from product development, to data handling, and to pitching to investors. After receiving my MSc in engineering physics, I worked as a quantitative analyst and data scientist in finance for several years before starting as head of data science at a major Swedish retail firm and CTO at Oppioo. As a result, I have a solid knowledge of data analysis as well as handling personal data and security issues – which is important not only in finance and retail but also in MedTech. As technology focuses more on integrating applications, processes, artificial intelligence and the Internet of Things, a CTO must follow the frontier of big data, streaming analytics, and cloud technology to remain innovative and stay competitive.Diverse skills allow you to think about specific problems in a different and often more strategic way. By being able to look at a problem from different angles and draw on a wealth of (not immediately relevant) experience, you can come up with innovative and creative solutions.All this experience is beneficial for developing an ai-driven patient-centered digital companion.


M7: You have recently partnered with 180 Degrees Consulting. Tell us about some developments at Oppioo that all of you are excited about
AB:
We have partnered with two great teams at 180 Degrees consulting and the London School of Economics. We are working together to get deeper market and customer insights that will be valuable in the development of both our product and business model. We are excited about the business opportunity this understanding gives us.


Limit time-wasting activities and people. Try to draw boundaries so that you can devote quality time to high-priority people and activities.



M7: What are the challenges that you face regarding handling AI technologies at Oppioo?
AB:
At Oppioo we want to improve the health of cancer patients, improve the patient experience and reduce the costs of health care. To do so, we need to work with patient data which means a lot of legal challenges. Medical data is sensitive and subject to privacy regulations that vary across jurisdictions. Companies that develop AI solutions for health care and medicine can run afoul of privacy laws if they’re not careful, and the MedTech industry is still finding the balance between access to data and protecting sensitive health data. Apart from data privacy concerns, there is also the issue of regulations. We want to be classified as a medical device to be able to give AI-driven individual healthcare advice to patients. However, it’s a time-consuming and difficult process to obtain CE marking. In fact, most of the challenges in AI are not technical applications of AI. There is the question of the quality and usability of data. In other industries, data is generally reliable and accurately measured (such as velocity data to predict highway traffic).  In healthcare, data can be subjective, and often inaccurate.


M7: What’s top of the list for what Oppioo wants to achieve by the end of this year and as you start moving into the next year?
AB:
At the end of this year, we aim to launch our product and get our first paying users. We are developing our platform together with cancer patients and health care providers to make it patient-centered. This is the biggest milestone we want to achieve and will be the start of our funding round. Next year will start with a post-product launch where we focus on understanding how well our product is accepted by end-users so that we can improve it. We will also continue building our community and expanding and strengthening our collaborations.


Diverse skills allow you to think about specific problems in a different and often more strategic way.



M7: Few years down the line, how do you see AI changing the world around us? Especially in the healthcare industry?
AB:
The future of AI in healthcare can be defined as better medical outcomes achieved through more accurate diagnosis and advanced treatment, as well as more informed and engaged patients empowered with easy access to healthcare support. AI will help us develop precision medicine and individualized healthcare with the patient in the center.  Precision health is a relatively new solution focused on preventative care which is based on patient data collected from genetic information, wearable devices and electronic health systems. Using information such as a patient’s lifestyle, genetic makeup, environment, and biometric healthcare data, AI-enabled precision health tools can identify potential risks and suggest preventative interventions.


M7: What are some of your preferred marketing channels given your target customers?
AB:
We want our users to start using Oppioo as early as possible during the cancer treatment, ideally already at the diagnosis stage. Hence Oppioo initially needs to be present where the newly diagnosed cancer patients are looking for information, such as health care providers, cancer societies, the regional or national care guides and social media groups. Therefore, established collaborations with reliable organizations and a frequent presence in social media channels are keys to our distribution chain. We are dependent on our network of collaboration partners, and every time we want to enter a market we need to find collaboration partners, such as local physiotherapists, health care providers etc. that are willing to promote the benefits of using Oppioo from an early stage of the cancer treatment.  The user can of course use Oppioo without these collaborations as well, but we believe that the best results will be reached when the user is supported by health care providers.


M7: Congratulations on being listed as one of the top ten talents in the Tech Vertical in the Swedish Nova 111-list. What is your secret to maintaining a healthy balance between work and personal life?
AB:
Thank you! I’m honored and grateful to have been included as one of the change-makers in Technology in Sweden.
My first advice is to work with something you enjoy since you spend so many hours of your day at work. But a more in-depth answer is that it’s very, very difficult to maintain a healthy balance even if you like what you work with. I think that work-life balance can be seen as a cycle, not an achievement; something to thrive for, that constantly changes with life. With that being said, I have a few life-hacks that I tend to come back to. The first is exercise and meditation.You can start small, e.g. by booking walking meetings instead of sitting in front of the computer. Ask yourself what’s currently causing you stress. Rethink your priorities, and put in time in the calendar now and then to reflect. A rational understanding of the decisions and priorities driving your life is important but equally important is emotional reflexivity - that is, the capacity to recognize how a situation is making you feel. Awareness of your emotional state is essential in order to determine the changes you want to make in your work and in your life. And last but not least: limit time-wasting activities and people. Try to draw boundaries so that you can devote quality time to high-priority people and activities. I personally like the Pomodoro Technique to help me focus.

ABOUT OPPIOO

Oppioo is a patient-centered product that supports patients to plan and execute physical activity in conjunction with the treatment plan. Oppioo predicts what activity gives optimal effect and when during the cancer treatment based on patient data and the patient’s energy level. To do so, Oppioo collects activity data from the user’s smartphone and user feedback to create a personalized automated coaching plan with the help of AI models. Oppioo allows for sharing data with health care providers.

More C-Suite on deck

‘AI will assist in creating a personalized experience for each individual,’ says Alexey Gubarev

Media 7 | October 17, 2023

Alexey Gubarev is a multifaceted individual, serving as an entrepreneur, investor, and philanthropist, with an unwavering dedication to Cyprus. His visionary leadership has played a pivotal role in the transformation of Cyprus into a recognized tech hub. Read on to know his thoughts about innovative technologies and its impact on future of healthcare industry.

Read More

Q&A with Matthew Sappern, CEO at PeriGen

Media 7 | September 30, 2021

Matthew Sappern, CEO at PeriGen, had served as a corporate officer for Eclipsys Corporation before and during its merger with Allscripts. Leading up to the merger, Sappern served as Eclipsys Senior Vice President of Professional Services, responsible for the company’s $100M consulting, implementation and training P&L. Sappern joined Eclipsys in January 2003, as VP of product development in the software engineering division. Over a time of three years, he came to run 75 percent of the development operation and oversaw the delivery of three critical enterprise software releases in record time for the company.

Read More

'AI is only as smart as the data and the people behind it', says Kyle Ryan

Media 7 | May 17, 2023

Kyle Ryan believes that innovative concepts, data-driven insights, precise engineering, and efficient execution combine to create great products. He also believes that leadership is essential for innovation. Read on to know his thoughts on the role of leadership and technology in healthcare industry.

Read More

‘AI will assist in creating a personalized experience for each individual,’ says Alexey Gubarev

Media 7 | October 17, 2023

Alexey Gubarev is a multifaceted individual, serving as an entrepreneur, investor, and philanthropist, with an unwavering dedication to Cyprus. His visionary leadership has played a pivotal role in the transformation of Cyprus into a recognized tech hub. Read on to know his thoughts about innovative technologies and its impact on future of healthcare industry.

Read More

Q&A with Matthew Sappern, CEO at PeriGen

Media 7 | September 30, 2021

Matthew Sappern, CEO at PeriGen, had served as a corporate officer for Eclipsys Corporation before and during its merger with Allscripts. Leading up to the merger, Sappern served as Eclipsys Senior Vice President of Professional Services, responsible for the company’s $100M consulting, implementation and training P&L. Sappern joined Eclipsys in January 2003, as VP of product development in the software engineering division. Over a time of three years, he came to run 75 percent of the development operation and oversaw the delivery of three critical enterprise software releases in record time for the company.

Read More

'AI is only as smart as the data and the people behind it', says Kyle Ryan

Media 7 | May 17, 2023

Kyle Ryan believes that innovative concepts, data-driven insights, precise engineering, and efficient execution combine to create great products. He also believes that leadership is essential for innovation. Read on to know his thoughts on the role of leadership and technology in healthcare industry.

Read More

Related News

Healthcare Analytics

SHL Medical partners with SteriPack Group to set up final assembly service

SHL Medical | January 24, 2024

SHL Medical, a world-leading solutions provider of advanced drug delivery systems and SteriPack Group, renowned global supplier of secondary packing and final assembly services to the pharmaceutical industry, enter a non-exclusive strategic partnership. Together, they aim to establish a pre-validated final assembly service at the SteriPack facility in Poland, enhancing the overall flexibility of supply chain strategies for their customers. In addition to SHL Medical's existing final assembly, labeling, and packaging­ services in the United States, this collaboration extends high-quality CMO options to Europe. Markus Puusepp, SHL Medical's Chief Growth Officer, expressed enthusiasm about the partnership, stating "This partnership is a significant addition to the Molly® platform value proposition. We share common values with SteriPack, from focus on the customer to a commitment to quality, making the decision to collaborate straightforward." Recognizing the importance of flexibility and time-to-market, especially in clinical production, the partnership with SteriPack will offer SHL Medical's customers highly flexible and personalized final assembly and packaging solutions. This is particularly beneficial for small batch handling in clinical supply and niche markets like rare diseases. Emphasizing the comprehensive capabilities of the Molly platform, SHL Medical aims to deliver right-sized solutions that ensure improved service, faster timelines, and a more streamlined supply chain for its diverse customer base. John Ward, SteriPack Group's VP Pharmaceutical Solutions commented "SteriPack Group looks forward to supporting SHL Medical and their customers in providing quality and flexible solutions to a fast- moving market. With an emphasis on creating service solutions designed around specific customer requirements, this partnership will make the process of working with the Molly® platform an easy decision." About SHL Medical As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by its company purpose – Enabling Patients' Independence – SHL Medical offers patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. It also offers final assembly, labeling, and packaging solutions for its drug delivery systems. In response to the rising trend in home therapy, SHL Medical has increased its developmental work in the digital healthcare sector to help improve the drug delivery ecosystem. Located across Switzerland, Taiwan, Sweden, and the US, SHL Medical's global team of experts collaborate seamlessly as one team in utilizing its comprehensive in-house manufacturing capabilities. Its solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into its designs and processes to contribute to a cleaner earth. About SteriPack Group SteriPack Group is a globally renowned contract packing and manufacturing organisation serving the pharmaceutical and medical device sectors respectively. With a strong emphasis on innovation, quality and compliance, SteriPack's services to the pharmaceutical industry include device design and development, final assembly, labelling, secondary packing, serialisation and aggregation of injectable formats including vials, pre-filled syringes, and autoinjectors. SteriPack's tailored customer-focused solutions make it an ideally suited supplier for small to medium-sized batch volumes required for a growing market of targeted therapies as well as clinical trials. Its proven capabilities in cleanroom assembly and labelling as well as secondary packing services for drug delivery systems and medical devices, combined with significant investment into growing cold chain storage capacity, have helped to make it a trusted partner to top global pharmaceutical companies.

Read More

Healthcare Analytics

Aya Healthcare Expands into UK with ID Medical Acquisition

Aya Healthcare | January 17, 2024

Aya Healthcare, the largest healthcare talent software and staffing company in the United States, today announced the acquisition of ID Medical, a leading workforce solutions provider in the United Kingdom (U.K.). ID Medical brings over 20 years of experience providing the National Health Service (NHS) and other healthcare organizations with innovative workforce solutions, including workforce management, international recruitment and temporary healthcare staffing. As part of the acquisition, ID Medical will make Aya Healthcare’s market-leading technology available to the NHS and U.K.-based clinicians. The companies plan to share best practices from each market with their respective clients. “We are excited about ID Medical joining the Aya family of brands. We believe that we will deliver enhanced value to our respective clients and clinicians through this cross-Atlantic collaboration,” said Alan Braynin, president and CEO of Aya Healthcare. ID Medical will continue to operate as its own brand in the U.K., supporting thousands of healthcare professionals and hundreds of healthcare organizations. “We are excited to join Aya in our shared mission to transform the healthcare industry worldwide,” said Deenu Patel, CEO of ID Medical. “With Aya’s support, we’ll have access to additional resources, technology and expertise to enhance our services and expand our impact.” About Aya Healthcare Aya Healthcare is the largest healthcare talent software and staffing company in the United States. Aya operates the world’s largest digital staffing platform delivering every component of healthcare-focused labor services, including travel nursing and allied health, per diem, permanent staff hiring, interim leadership, locum tenens and non-clinical professionals. Aya’s software suite, which includes vendor management, float pool technology, provider services and predictive analytics, provides hospital systems greater efficiencies, superior operating results and reduced labor costs. While technology drives efficiency and scale, Aya’s 7,000+ global employees power the company to deliver unparalleled accountability and exceptional experiences for clients and clinicians. Aya’s company culture is rooted in giving back and supports organizations around food security, education, healthcare, safe shelter and equity.

Read More

Health Technology

Axxess Launches New Axxess Connect Solution to Accelerate Health Information Exchange

Axxess | January 23, 2024

Axxess, the leading global technology innovator for healthcare at home, launched a new product called Axxess Connect, a groundbreaking interoperability solution. This new product will revolutionize the way Axxess users connect and share data with healthcare providers and specialists, further enhancing care coordination, improving patient outcomes and driving the future by enabling new care models and value-based care. "Axxess Connect is a new benchmark for interoperability in healthcare," says Tim Ingram, Executive Vice President of Interoperability at Axxess. "By working with our partner Kno2 we can now connect our solutions to help accelerate the exchange of health information securely across any network. This means our clients will have easier access to a broader range of providers and specialists, making data sharing and referrals more efficient." By being Kno2 Connected™, Axxess Connect, enables the secure, effortless, and maximized exchange of patient information across patients, providers, payers and HIT vendors. ­­­­The solution meets data security and compliance requirements in accordance with HITRUST and HIPAA regulation for privacy, data sharing and healthcare communication standards supported by national and regional frameworks including Direct Trust, Carequality and most recently, TEFCA. This ensures that patient data is interoperable, secured and protected when shared across systems. "Our collaboration with Kno2 not only improves the overall experience for our users, but it also reduces the administrative load on healthcare providers," said Ingram. "By minimizing time spent on administrative tasks, our clients can focus more on providing quality patient care." Added Theresa Bell, Co-founder, President and Chief Technology Officer of Kno2: "By seamlessly connecting Axxess users with healthcare providers and specialists, we are breaking down barriers and revolutionizing the way data is shared in every care setting. Axxess Connect represents the power of the partnership and the value of being Kno2 Connected. Together, we are revolutionizing care delivery and thoughtfully solving healthcare's biggest problems." Axxess Connect will first be available to Axxess Palliative Care clients before eventually being rolled out to the entire Axxess suite of solutions for home health, hospice and home care. About Axxess Axxess is the leading global technology innovator for healthcare at home, focused on solving the most complex industry challenges. Trusted by more than 9,000 organizations that serve more than 5 million patients worldwide, Axxess offers a complete suite of easy-to-use software solutions that empower home health, home care, hospice, and palliative providers to make healthcare in the home human again. Multiple independent certifications have confirmed that Axxess has the most secure and industry-compliant software available for providers. The company's collaborative culture focused on innovation and excellence is recognized nationally as a "Best Place to Work."

Read More

Healthcare Analytics

SHL Medical partners with SteriPack Group to set up final assembly service

SHL Medical | January 24, 2024

SHL Medical, a world-leading solutions provider of advanced drug delivery systems and SteriPack Group, renowned global supplier of secondary packing and final assembly services to the pharmaceutical industry, enter a non-exclusive strategic partnership. Together, they aim to establish a pre-validated final assembly service at the SteriPack facility in Poland, enhancing the overall flexibility of supply chain strategies for their customers. In addition to SHL Medical's existing final assembly, labeling, and packaging­ services in the United States, this collaboration extends high-quality CMO options to Europe. Markus Puusepp, SHL Medical's Chief Growth Officer, expressed enthusiasm about the partnership, stating "This partnership is a significant addition to the Molly® platform value proposition. We share common values with SteriPack, from focus on the customer to a commitment to quality, making the decision to collaborate straightforward." Recognizing the importance of flexibility and time-to-market, especially in clinical production, the partnership with SteriPack will offer SHL Medical's customers highly flexible and personalized final assembly and packaging solutions. This is particularly beneficial for small batch handling in clinical supply and niche markets like rare diseases. Emphasizing the comprehensive capabilities of the Molly platform, SHL Medical aims to deliver right-sized solutions that ensure improved service, faster timelines, and a more streamlined supply chain for its diverse customer base. John Ward, SteriPack Group's VP Pharmaceutical Solutions commented "SteriPack Group looks forward to supporting SHL Medical and their customers in providing quality and flexible solutions to a fast- moving market. With an emphasis on creating service solutions designed around specific customer requirements, this partnership will make the process of working with the Molly® platform an easy decision." About SHL Medical As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by its company purpose – Enabling Patients' Independence – SHL Medical offers patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. It also offers final assembly, labeling, and packaging solutions for its drug delivery systems. In response to the rising trend in home therapy, SHL Medical has increased its developmental work in the digital healthcare sector to help improve the drug delivery ecosystem. Located across Switzerland, Taiwan, Sweden, and the US, SHL Medical's global team of experts collaborate seamlessly as one team in utilizing its comprehensive in-house manufacturing capabilities. Its solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into its designs and processes to contribute to a cleaner earth. About SteriPack Group SteriPack Group is a globally renowned contract packing and manufacturing organisation serving the pharmaceutical and medical device sectors respectively. With a strong emphasis on innovation, quality and compliance, SteriPack's services to the pharmaceutical industry include device design and development, final assembly, labelling, secondary packing, serialisation and aggregation of injectable formats including vials, pre-filled syringes, and autoinjectors. SteriPack's tailored customer-focused solutions make it an ideally suited supplier for small to medium-sized batch volumes required for a growing market of targeted therapies as well as clinical trials. Its proven capabilities in cleanroom assembly and labelling as well as secondary packing services for drug delivery systems and medical devices, combined with significant investment into growing cold chain storage capacity, have helped to make it a trusted partner to top global pharmaceutical companies.

Read More

Healthcare Analytics

Aya Healthcare Expands into UK with ID Medical Acquisition

Aya Healthcare | January 17, 2024

Aya Healthcare, the largest healthcare talent software and staffing company in the United States, today announced the acquisition of ID Medical, a leading workforce solutions provider in the United Kingdom (U.K.). ID Medical brings over 20 years of experience providing the National Health Service (NHS) and other healthcare organizations with innovative workforce solutions, including workforce management, international recruitment and temporary healthcare staffing. As part of the acquisition, ID Medical will make Aya Healthcare’s market-leading technology available to the NHS and U.K.-based clinicians. The companies plan to share best practices from each market with their respective clients. “We are excited about ID Medical joining the Aya family of brands. We believe that we will deliver enhanced value to our respective clients and clinicians through this cross-Atlantic collaboration,” said Alan Braynin, president and CEO of Aya Healthcare. ID Medical will continue to operate as its own brand in the U.K., supporting thousands of healthcare professionals and hundreds of healthcare organizations. “We are excited to join Aya in our shared mission to transform the healthcare industry worldwide,” said Deenu Patel, CEO of ID Medical. “With Aya’s support, we’ll have access to additional resources, technology and expertise to enhance our services and expand our impact.” About Aya Healthcare Aya Healthcare is the largest healthcare talent software and staffing company in the United States. Aya operates the world’s largest digital staffing platform delivering every component of healthcare-focused labor services, including travel nursing and allied health, per diem, permanent staff hiring, interim leadership, locum tenens and non-clinical professionals. Aya’s software suite, which includes vendor management, float pool technology, provider services and predictive analytics, provides hospital systems greater efficiencies, superior operating results and reduced labor costs. While technology drives efficiency and scale, Aya’s 7,000+ global employees power the company to deliver unparalleled accountability and exceptional experiences for clients and clinicians. Aya’s company culture is rooted in giving back and supports organizations around food security, education, healthcare, safe shelter and equity.

Read More

Health Technology

Axxess Launches New Axxess Connect Solution to Accelerate Health Information Exchange

Axxess | January 23, 2024

Axxess, the leading global technology innovator for healthcare at home, launched a new product called Axxess Connect, a groundbreaking interoperability solution. This new product will revolutionize the way Axxess users connect and share data with healthcare providers and specialists, further enhancing care coordination, improving patient outcomes and driving the future by enabling new care models and value-based care. "Axxess Connect is a new benchmark for interoperability in healthcare," says Tim Ingram, Executive Vice President of Interoperability at Axxess. "By working with our partner Kno2 we can now connect our solutions to help accelerate the exchange of health information securely across any network. This means our clients will have easier access to a broader range of providers and specialists, making data sharing and referrals more efficient." By being Kno2 Connected™, Axxess Connect, enables the secure, effortless, and maximized exchange of patient information across patients, providers, payers and HIT vendors. ­­­­The solution meets data security and compliance requirements in accordance with HITRUST and HIPAA regulation for privacy, data sharing and healthcare communication standards supported by national and regional frameworks including Direct Trust, Carequality and most recently, TEFCA. This ensures that patient data is interoperable, secured and protected when shared across systems. "Our collaboration with Kno2 not only improves the overall experience for our users, but it also reduces the administrative load on healthcare providers," said Ingram. "By minimizing time spent on administrative tasks, our clients can focus more on providing quality patient care." Added Theresa Bell, Co-founder, President and Chief Technology Officer of Kno2: "By seamlessly connecting Axxess users with healthcare providers and specialists, we are breaking down barriers and revolutionizing the way data is shared in every care setting. Axxess Connect represents the power of the partnership and the value of being Kno2 Connected. Together, we are revolutionizing care delivery and thoughtfully solving healthcare's biggest problems." Axxess Connect will first be available to Axxess Palliative Care clients before eventually being rolled out to the entire Axxess suite of solutions for home health, hospice and home care. About Axxess Axxess is the leading global technology innovator for healthcare at home, focused on solving the most complex industry challenges. Trusted by more than 9,000 organizations that serve more than 5 million patients worldwide, Axxess offers a complete suite of easy-to-use software solutions that empower home health, home care, hospice, and palliative providers to make healthcare in the home human again. Multiple independent certifications have confirmed that Axxess has the most secure and industry-compliant software available for providers. The company's collaborative culture focused on innovation and excellence is recognized nationally as a "Best Place to Work."

Read More

Spotlight

Oppioo

Oppioo

Oppioo is a patient-centered product that supports patients to plan and execute physical activity in conjunction with the treatment plan. Oppioo predicts what activity gives optimal effect and when during the cancer treatment based on patient data and the patient’s energy level. To do so, Oppioo col...

Events

Resources

resource image

Health Technology, Digital Healthcare

Exploring EHR Trends: A Path to Healthcare Transformation

Article

resource image

Health Technology, Digital Healthcare

Top 10 Best Practices for EHR Ethical Issues

Article

resource image

Health Technology, Digital Healthcare

Exploring EHR Trends: A Path to Healthcare Transformation

Article

resource image

Health Technology, Digital Healthcare

Top 10 Best Practices for EHR Ethical Issues

Article

Events